Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

Did the effectiveness of nirsevimab treatment in preventing respiratory syncytial virus (RSV) type B bronchiolitis during pediatric emergency department visits remain stable during the second season of implementation?In this test-negative case-control study of 636 infants, the estimated effectiveness of nirsevimab treatment was 83.2% during the first season of implementation and 89.3% during the second season.This study suggests that, although RSV type B resistant strains had been recently identified, the effectiveness of nirsevimab treatment at preventing RSV type B bronchiolitis remained high during the second season of national implementation in France.

Corresponding Author: Lea Lenglart, MD, Pediatric Emergency Department, Robert Debré Hospital, Assistance Publique–Hôpitaux de Paris, 48 Boulevard Sérurier, Paris 75019, France (lea.lenglart@aphp.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.